Skip to main content

Plasma Fractionation Market to Worth USD 58.24 Billion by 2030 | Skyquest Technology

Plasma fractionation market is segmented based on product, method, application, end use. Based on product, the market is segmented into albumin, immunoglobulins, coagulation factors, protease inhibitors. In terms of method, the market is segmented into centrifugation, depth filtration, and chromatography. With respect to segmentation by application, the market is segmented into neurology, hematology, oncology, immunology, and pulmonology. Based on categorization by end use, the market is segmented into hospitals & clinics, clinical research, and others- Industry forecast 2023-2030

Westford, USA, Jan. 10, 2024 (GLOBE NEWSWIRE) — According to SkyQuest, the global plasma fractionation market is experiencing robust growth, driven by several key factors. One significant contributor is the increasing proportion of elderly individuals worldwide, who are more susceptible to rare medical conditions that necessitate using blood derivatives and plasma-based therapies.

Get sample copy of this report:

https://www.skyquestt.com/sample-request/plasma-fractionation-market

Browse in-depth TOC on the “Plasma Fractionation Market”     

  • Pages – 157
  • Tables –  119
  • Figures – 77

The global plasma fractionation market is poised for promising growth, driven by a convergence of factors that create favorable business opportunities for industry participants. Increasing research and development efforts are paving the way for innovative advancements in plasma-based therapies and products.

Report Scope & Segmentation:                                        

AttributesDetails
Market Size in 2022USD 30.87 Billion
2030 Value ProjectionUSD 58.24 Billion
CAGR8.3%
Forecast Period2023-2030
Segments Covered
  • Product
  • Method
  • Application
  • End Use

 

Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Prominent Players in the Plasma Fractionation Market

  • CSL Behring
  • Grifols
  • Octapharma
  • Baxalta/Shire
  • Kedrion
  • China Biologic Products Holdings
  • Sanquin
  • Bio Products Laboratory
  • Japan Blood Products Organization
  • LFB Group
  • Shanghai RAAS Blood Products
  • Green Cross Corporation
  • Baxter International Inc.
  • Takeda Pharmaceutical Company Limited
  • Beijing Tiantan Biological Products
  • Biotest AG
  • China National Pharmaceutical Group Co. (Sinopharm)
  • GC Pharma
  • ADMA Biologics
  • Emergent BioSolutions.

Browse summary of the report and Complete Table of Contents (ToC):

https://www.skyquestt.com/report/plasma-fractionation-market

Immunoglobulin Segment is Expected to Grow in the Market Due to Multifaceted Utility of Immunoglobulins

Immunoglobulin segment has emerged as the dominant player in the plasma fractionation market, commanding a significant share. This dominance is attributed to the multifaceted utility of immunoglobulins, which are employed in treating, diagnosing, and managing a wide array of metabolic disorders.

The markets in North America have asserted their dominance in the plasma fractionation market, holding a commanding share of 53.93%. This remarkable market position is the result of a combination of factors. The region has witnessed a notable uptick in the prevalence of respiratory illnesses, underlining the critical need for plasma-derived therapies in treating such conditions.

Neurology Segment is Expected to Dominate the Market Due to the Alarming Surge in the Incidence of Neurological Diseases

Neurology category emerged as the undisputed leader in the global plasma fractionation market, building a substantial revenue of USD 8,356.9. This commanding dominance can be attributed to a compelling driver— the alarming surge in the incidence of neurological diseases worldwide.

Regional markets in the Asia Pacific region are experiencing significant expansion in the plasma fractionation market, driven by various factors. Tighter government regulations have prompted a more structured and quality-focused approach to plasma-based therapies, instilling greater confidence among healthcare providers and patients.

A comprehensive analysis of the major players in the plasma fractionation market has been recently conducted in a report. The report encompasses various aspects, including collaborations, mergers, innovative business policies, and strategies, providing valuable insights into key trends and breakthroughs in the market. Furthermore, the report scrutinizes the market share of the top segments and presents a detailed geographic analysis. Lastly, the report highlights the major players in the industry and their endeavours to develop innovative solutions to cater to the growing demand.

Key Developments in the Plasma Fractionation Market

  • In 2022, Grifols marked a significant milestone by inaugurating a state-of-the-art facility at its global manufacturing and distribution hub in Dublin, Ireland. This cutting-edge facility is dedicated to purifying and filling albumin, a critical component in plasma-derived therapies. Grifols’ strategic investment in this facility underscores its commitment to ensuring a robust supply of essential medical products to meet the growing demand for plasma-derived treatments.
  • In 2022, CSL Behring K.K. achieved a significant milestone when it received manufacturing and marketing approval from the Ministry of Health, Labor and Welfare of Japan for Berinert S.C. Injection 2000. This product is a lyophilized human C1-esterase inhibitor concentrate formulated for subcutaneous (SC) injection in plasma derivatives.

Speak to Analyst for your custom requirements:

https://www.skyquestt.com/speak-with-analyst/plasma-fractionation-market

 Key Questions Answered in Plasma Fractionation Market Report

  • What specific growth drivers are projected to impact the market during the forecast period?
  • List the top companies in the market and explain how they have achieved their positions of influence.
  • In what ways do regional trends and patterns differ within the global market, and how these differences shape the market’s future growth?

Related Reports in SkyQuest’s Library:

Global Polymerase Chain Reaction (PCR) Market

Global Induced Pluripotent Stem Cells Production Market 

Global Protein Therapeutics Market

Global Chemiluminescence Immunoassay Analyzers Market

Global Biobanking Market

About Us:

SkyQuest Technology is leading growth consulting firm providing market intelligence, commercialization and technology services. It has 450+ happy clients globally.

Address:

1 Apache Way, Westford, Massachusetts 01886

Phone:

USA (+1) 617-230-0741

Email: sales@skyquestt.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.